MedTrace Logo

Understanding Hemophilia A and B Drug Dosage Administration Patterns

NCT03248141 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2019-05-20

Study results available
· View outcomes & findings →

Summary

Study Design

A prospective observational, cross-sectional epidemiological study in U.S. site-based clinical practice settings.

30 sites will enroll approximately 300 patients

Participating patients - or their caregiver in the case of patients under the age of 18 - will be consented to participate.

Physicians complete a retrospective chart review on each enrolled patient.

Patients will complete a one-time study questionnaire.

Conditions

Interventions

DRUG

Hemophilia B standard half-life

Benefix

DRUG

Hemophilia B extended half-life

Alprolix

DRUG

Hemophilia A standard half-life

Xyntha and other standard half-life agents

DRUG

Hemophilia A extended half-life

Eloctate and Adynovate

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2018-03-14
Completion
2018-03-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03248141 on ClinicalTrials.gov